ÂÜÀòÂÒÂ×

Mr. Monnet joined the PDL BioPharma Board of Directors in December 2018. He serves as a Director of PDL BioPharma. He joined the Company in 2017 as President and assumed the dual role of President and Chief Executive Officer in 2018. Before joining PDL, Mr. Monnet served as senior vice president and chief marketing officer of Alexion Pharmaceuticals from 2014 to 2015, where he was responsible for commercial operations in the U.S. and Latin America and oversaw new products and global business operations functions.

From 2002 to 2013, he was a senior executive at Amgen Inc., where he served in a number of key commercial leadership positions in the U.S. and internationally. As vice president and general manager for Amgen’s Inflammation Business Unit in 2011 to 2013, he was responsible for accelerating the growth of the Enbrel® franchise in the highly competitive U.S. market. Prior to this, he served as vice president and head of Amgen’s Global Marketing and Commercial Development, where he led the marketing strategies and global launches of new products across a range of therapeutic areas.

From 2002 through 2006, Mr. Monnet was based in Zug, Switzerland, where he served as Amgen’s Vice President of International Marketing and Business Operations, building Amgen’s international commercial capability and leading the creation of its successful international franchises in oncology and nephrology. Before joining Amgen, Mr. Monnet held positions of increasing responsibility in line commercial management and global marketing over 19 years at Schering-Plough – including General Manager of its affiliate in the UK and Republic of Ireland — Ciba-Geigy and Alza Corporation. Mr. Monnet holds a business degree from EDHEC Business School in Lille, France, and an MBA from INSEAD in Fontainebleau, France.

Mr. Monnet brings the Board of Directors of PDL BioPharma a strong understanding of the pharmaceutical and biotechnology industries and experience in the commercialization of pharmaceutical products.